HCW Biologics Inc
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
HCWB$1.02-1.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of changes in stockholders’ equity (deficit)
Condensed Statements of Changes in Stockholders’ Equity (Deficit)
For the Six Months Ended June 30, 2023 and 2024
| Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’ | ||||||
| Shares · Amount · Capital · Deficit · Equity | ||||||
| Balance, December 31, 2022 | 35,876,440 | $3,588 | $82,962,964 | $(45,538,046) | $37,428,506 | |
| Issuance of Common Stock upon exercise of stock options | 10,195 | 1 | 1,900 | — | 1,901 | |
| Stock-based compensation | — | — | 259,206 | — | 259,206 | |
| Net loss | — | — | — | (5,070,686) | (5,070,686) | |
| Balance, March 31, 2023 | 35,886,635 | $3,589 | $83,224,070 | $(50,608,732) | $32,618,927 | |
| Issuance of Common Stock upon exercise of stock options | 40,086 | 4 | 7,708 | — | 7,712 | |
| Stock-based compensation | — | — | 263,423 | 263,423 | ||
| Net loss | — | — | — | (4,304,420) | (4,304,420) | |
| Balance, June 30, 2023 | 35,926,721 | $3,593 | $83,495,201 | $(54,913,152) | $28,585,642 | |
| Stockholders’ Equity (Deficit) | |||||
|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’ | |||||
| Shares | Amount | Capital | Deficit | Equity (Deficit) | |
| Balance, December 31, 2023 | 36,025,104 | $3,603 | $83,990,437 | $(70,532,323) | $13,461,717 |
| Issuance of Common Stock upon exercise of stock options | 12,572 | 1 | 2,254 | — | 2,255 |
| Issuance of Common Stock upon equity subscription | 1,785,718 | 178 | 2,499,827 | — | 2,500,005 |
| Stock-based compensation | — | — | 244,685 | — | 244,685 |
| Net loss | — | — | — | (7,468,061) | (7,468,061) |
| Balance, March 31, 2024 | 37,823,394 | $3,782 | $86,737,203 | $(78,000,384) | $8,740,601 |
| Issuance of Common Stock upon exercise of stock options | — | — | — | — | — |
| Stock-based compensation | — | — | 239,821 | — | 239,821 |
| Net loss | — | — | — | (15,280,191) | (15,280,191) |
| Balance, June 30, 2024 | 37,823,394 | $3,782 | $86,977,024 | $(93,280,575) | $(6,299,769) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.